A Study Comparing Ezetimibe Plus Simvastatin Versus Simvastatin Alone in Patients at Risk for Heart Disease (0653-023)(COMPLETED)

NCT00551447 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

616

Enrollment

INDUSTRY

Sponsor class

Conditions

Coronary Disease

Interventions

DRUG: MK0653, ezetimibe / Duration of Treatment: 27 Weeks
DRUG: MK0733, simvastatin / Duration of Treatment: 27 Weeks
DRUG: Comparator: simvastatin / Duration of Treatment: 27 Weeks

Sponsor

Organon and Co